Login to Your Account



Clinic Roundup


Monday, December 17, 2012
• Biotron Ltd., of Sydney, Australia, said it expects to deliver preliminary data from a Phase Ib/IIa study of lead HIV drug, BIT225, in the March quarter of 2013. BIT225 is designed to specifically target HIV in reservoir cells to stop the ongoing cycle of infection in the body.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription